Skip to main content
main-content

01.12.2011 | Hepatobiliary Tumors | Ausgabe 13/2011

Annals of Surgical Oncology 13/2011

Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis

Zeitschrift:
Annals of Surgical Oncology > Ausgabe 13/2011
Autoren:
MD, MPH Skye C. Mayo, MD Mechteld C. de Jong, MD Mark Bloomston, MD Carlo Pulitano, MD Bryan M. Clary, MD Srinevas K. Reddy, MD, MS T. Clark Gamblin, MD Scott A. Celinski, MD David A. Kooby, MD Charles A. Staley, MD Jayme B. Stokes, MD Carrie K. Chu, MD David Arrese, MD Alessandro Ferrero, MD Richard D. Schulick, MD Michael A. Choti, MD Jean-Francois H. Geschwind, MD Jennifer Strub, MD Todd W. Bauer, MD Reid B. Adams, MD Luca Aldrighetti, MD Gilles Mentha, MD Lorenzo Capussotti, MD, MPH Timothy M. Pawlik
Wichtige Hinweise
Presented at the Society of Surgical Oncology 64th Annual Meeting, San Antonio, TX, March 4, 2011.

Abstract

Background

Management of patients with neuroendocrine liver metastasis (NELM) remains controversial. We sought to examine the relative efficacy of surgical management versus intra-arterial therapy (IAT) for NELM and determine factors predictive of survival.

Methods

A total of 753 patients who had surgery (n = 339) or IAT (n = 414) for NELM from 1985 to 2010 were identified from nine hepatobiliary centers. Clinicopathologic data were assessed with regression modeling and propensity score matching.

Results

Most patients had a pancreatic (32%) or a small bowel (27%) primary tumor; 47% had a hormonally active tumor. There were statistically significant differences in characteristics between surgery versus IAT groups (hormonally active tumors: 28 vs. 48%; hepatic tumor burden >25%: 52% vs. 76%) (all P < 0.001). Among surgical patients, most underwent hepatic resection alone without ablation (78%). The median number of IAT treatments was 1 (range, 1–4). Median and 5-year survival of patients treated with surgery was 123 months and 74% vs. 34 months and 30% for IAT (P < 0.001). In the propensity-adjusted multivariate Cox model, asymptomatic disease (hazard ratio 2.6) was strongly associated with worse outcome (P = 0.001). Although surgical management provided a survival benefit over IAT among symptomatic patients with >25% hepatic tumor involvement, there was no difference in long-term outcome after surgery versus IAT among asymptomatic patients (P = 0.78).

Conclusions

Asymptomatic patients with a large (>25%) burden of liver disease benefited least from surgical management and IAT may be a more appropriate treatment strategy. Surgical management of NELM should be reserved for patients with low-volume disease or for those patients with symptomatic high-volume disease.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 13/2011

Annals of Surgical Oncology 13/2011 Zur Ausgabe
  1. Sie können e.Med Chirurgie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise